Holen Sie sich die Stockscreener-App
131.28
2.40%
3.08
Handel nachbörslich:
131.28
Schlusskurs vom Vortag:
$128.20
Offen:
$131.33
24-Stunden-Volumen:
7.15M
Relative Volume:
2.94
Marktkapitalisierung:
$13.96B
Einnahmen:
$612.78M
Nettoeinkommen (Verlust:
$-86.37M
KGV:
-150.90
EPS:
-0.87
Netto-Cashflow:
$-62.91M
1W Leistung:
+2.11%
1M Leistung:
+3.22%
6M Leistung:
+79.84%
1J Leistung:
+83.63%
1-Tages-Spanne:
$131.20
$131.35
1-Wochen-Bereich:
$128.04
$131.35
52-Wochen-Spanne:
$63.30
$131.35
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Firmenname
Intra Cellular Therapies Inc
Sektor
Telefon
(646) 440-9333
Adresse
135 ROUTE 202/206, BEDMINSTER, NY
Vergleichen Sie ITCI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
170.55 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.59 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-01-31 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-11 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-08-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-22 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Eingeleitet | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-10 | Eingeleitet | Goldman | Buy |
| 2020-02-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-31 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-12 | Eingeleitet | Jefferies | Buy |
| 2018-02-26 | Eingeleitet | JP Morgan | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-11-08 | Hochstufung | SunTrust | Hold → Buy |
| 2017-09-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-29 | Herabstufung | SunTrust | Buy → Neutral |
Alle ansehen
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
Intra-Cellular Therapies progresses in Johnson & Johnson merger By Investing.com - Investing.com Australia
Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance
GW&K Investment Management LLC Sells 6,734 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Phocas Financial Corp. Has $241,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Equities Analysts Offer Predictions for ITCI FY2025 Earnings - MarketBeat
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Where are the Opportunities in (ITCI) - Stock Traders Daily
Wealthspire Advisors LLC Acquires New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ING Groep NV Purchases Shares of 12,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho - MarketBeat
HealthInvest Partners AB Sells 13,440 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Ieq Capital LLC - MarketBeat
New York State Common Retirement Fund Has $6.40 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $129 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $129 - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Alberta Investment Management Corp - MarketBeat
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc.ITCI - Business Wire
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Needham & Company LLC Reaffirms Hold Rating for Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - The Bakersfield Californian
Intra-Cellular Therapies Reports Strong 2024 Growth - TipRanks
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Mizuho cuts Intra-Cellular stock rating, lowers price target - Investing.com India
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140 - Marketscreener.com
Principal Financial Group Inc. Sells 46,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week HighWhat's Next? - MarketBeat
TimesSquare Capital Management LLC Increases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular: Q4 Earnings Snapshot - CTPost
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire
Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects - TipRanks
Intra-Cellular Therapies, Inc. SEC 10-K Report - TradingView
Form 10-K Intra-Cellular Therapies For: Dec 31 - StreetInsider.com
Intra-Cellular: Q4 Earnings Snapshot -February 21, 2025 at 08:18 am EST - Marketscreener.com
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises -February 21, 2025 at 08:17 am EST - Marketscreener.com
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss - Marketscreener.com
Intra-Cellular Therapies Reports Strong Fourth Quarter 2024 Results with 51% Increase in CAPLYTA Net Sales and FDA Review Acceptance for New Indication - Nasdaq
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Revenue $199.2M, vs. FactSet Est of $193.4M - Marketscreener.com
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire Inc.
Savant Capital LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update - MarketBeat
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat - MSN
StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year HighHere's What Happened - MarketBeat
Finanzdaten der Intra Cellular Therapies Inc-Aktie (ITCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intra Cellular Therapies Inc-Aktie (ITCI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Option Exercise |
12.73 |
51,697 |
658,103 |
1,122,026 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
3.50%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):